-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

Barchart·12/23/2025 07:19:00
Listen to the news

IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company's inFoods® IBS test, establishing a national Medicare payment rate of $300 under the Clinical Laboratory Fee Schedule (CLFS). The pricing will apply to claims for InFoods IBS tests that Medicare approves and pays with dates of service on or after January 1, 2026.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.